Dermatologist Prof. Jörg Wenzel of Bonn University Hospital and University of Bonn has collaborated with Incyte, a U.S.-based global biopharmaceutical company, to develop a strategy for treating patients with severe pruritus (prurigo nodularis) with ruxolitinib cream. The University of Bonn and Incyte have now entered into an agreement whereby Incyte has acquired the rights to a related joint patent application from Bonn.
"Chronic itching is a common and very distressing condition in our patient population," says Jörg Wenzel, co-inventor and senior physician at the Centre for Skin Diseases at the UKB. "The causes are very diverse and, unfortunately, the established drugs, such as anti-histamines, which are known from allergic diseases, do not help for a long time in all patients." In prurigo nodularis, the unbearable itching tempts sufferers to scratch intensively and permanently. Over time, painful papules form, which themselves cause itching - thus creating a vicious circle. The disease is extremely stressful for those affected - anxiety, depression or even suicidal thoughts can develop as a consequence - and is a major therapeutic challenge. Incyte is currently evaluating ruxolitinib cream for the treatment of prurigo nodularis in two randomized Phase III clinical trials.
New therapeutic approach for prurigo nodularis